Each year nearly 900,000 US children up to 19 years of age sustain a traumatic brain injury (TBI) requiring hospitalization or emergency treatment. In this themed issue of NeuroRehabilitation experts share their work related to the challenges associated with return to school (RTS) for children and adolescents with TBI and discuss emerging trends, new developments, and recommendations on how they impact parents, carers and students and quality of life.
Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.
Research by Mariella Filbin, MD, PhD, and others in the Brain Tumor Center at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center has uncovered new details about how these rare tumors develop and grow that could someday inform specialized treatment options.
Newcastle and Hunter-based researchers have discovered a drug combination that could improve the life expectancy of children with brain cancer.
Protoporphyrin can be a beacon to the neurosurgeon through its use as a highly fluorescent visual aid when a special fluorescence detection microscope is used during surgery. Credit: Dr. Nader Sanai/ Ivy Brain Tumor Center
In a recent talk, a CHOC pediatric oncologist discussed trends, challenges and advancements for treating brain tumors in kids.
First-of-its-Kind Open-Analysis Platform for Pediatric Brain Tumors Provides Robust Data Resource for Childhood Cancer Research
Collaboration among CHOP, Alex’s Lemonade Stand Foundation, the Pacific Pediatric Neuro-Oncology Consortium, and Children’s Brain Tumor Network paves the way for new collaborative models to accelerate discoveries
Mount Sinai Health System and Memorial Sloan Kettering Cancer Center researchers have developed a new drug delivery approach that uses nanoparticles to enable more effective and targeted delivery of anti-cancer drugs to treat brain tumors in children.
The first in-human study of a new immunotherapy that blocks a natural enzyme that tumors commandeer for their protection was well tolerated by children with relapsed brain tumors and enabled many to have unexpected months of a more normal life, researchers say.
The brain is shielded from most toxins and pathogens by a highly complex network of blood vessels—the blood-brain barrier—that restricts the size and chemical composition of molecules that can cross through it and into brain tissue.